Pharma

GW Pharma Oncology Is Potential Underrated

Glioma test results hold out promise.<p>Long-standing hopes for cannabis-based treatments for cancer have not been realised in general so far.<p>GW Pharma …

Investing

India's Pharma Barons Are Reporting Delays in Digitizing Labs - Bloomberg

Heads of two of India’s largest drug makers said integration of electronic systems to prevent quality lapses in factories is going slower than …

Innovation

Cowen likes Aerie Pharma, sees 58% upside

Cowen & Company initiates coverage on Aerie Pharmaceuticals (NASDAQ:AERI) with an Outperform rating and $70 (58% upside) price target.<p>Now read: <b>Aerie</b> …

Business

Sworn to secrecy, drugstores stay silent as customers overpay

Eric Pusey has to bite his tongue when customers at his pharmacy cough up copayments far higher than the cost of their low-cost generic drugs, thinking their insurance is getting them a good deal.<p>Pusey's contracts with drug-benefit managers at his Medicap Pharmacy in Olyphant, Penn., bar him from …

Health Care

Ties to Gilead, AbbVie and BMS raise questions about hep C drug value studies

For years, Big Pharma has utilized the help of academic experts at Precision Health Economics (PHE) to carry their message that groundbreaking …

Health Care

ANI Pharma acquires two hypotension meds

ANI Pharmaceuticals (NASDAQ:ANIP) acquires Inderal XL from Cranford Pharmaceuticals, LLC and InnoPran XL from Holmdel Pharmaceuticals LP for an …

Novartis' Zykadia gets a front-line boost in lung cancer race against Roche

Novartis isn’t letting its cross-town rival get all the regulatory attention when it comes to ALK+ metastatic non-small cell lung cancer.<p>Thursday, it …

Cancer

Merck swallows $2.9B write-down of experimental hep c drug as market plummets

Just how drastically is the market for hepatitis c drugs shrinking? The situation is so bad that less than three years after shelling out $3.9 …

Markets

Lawmakers decry Army’s planned Zika vaccine license to Sanofi

After some nonprofit organizations made noise about the U.S. Army’s plans to license a Zika vaccine to Sanofi, several lawmakers are chiming in to …

Viruses

Pfizer plant hit with warning letter has history of FDA problems

The Pfizer fill/finish plant whose manufacturing problems has gut punched the expected approval of a generic of Teva’s long-acting Copaxone is a …

Pfizer

Intercept Pharma net loss widens in Q4 and FY16

Intercept Pharmaceuticals (ICPT -3.6%) Q4 results: Revenues: $13.8M; Operating Loss: ($114M) (-28.2%); Net Loss: ($120M) (-35.9%); Loss Per Share: …

Business

Bristol-Myers Looms as Pharma's Next Megadeal as Activists Join - Bloomberg

Bristol-Myers Squibb Co. was once one of the drug industry’s highest-flying companies. Now the pharmaceutical giant has gone from predator to prey, …

Investing

Mass rep exodus at Valeant could seriously thwart its GI plans: analyst

Remember when Valeant was counting on a sales force beef-up to revive its struggling gastrointestinal franchise? It may have just run into a big …

Markets

China Expands Drug Insurance Coverage in Boost to Pharma Stocks - Bloomberg

China expanded the list of medicines covered nationwide by government insurance for the first time since 2009, a move that sent the shares of Chinese …

China

Top 10 U.S. patent losses of 2017

Among the many meds that’ll lose patent protection in the U.S. this year are 10 drugs that each contribute in a big way for top drugmakers. Eli …

Investing

One more time: We're not buying Valeant, Allergan CEO insists

Allergan CEO Brent Saunders has said it before, and he’ll say it again: He’s not interested in buying Valeant. He might "take five minutes" to think …

Markets

Making (good) deals is hard to do, Gilead CEO says, but he's working on it

With hep C sales tumbling—and no sure sign of a bottom ahead—management at Gilead has been in the hot seat for quite some time to get a deal done. On …

Markets

Billionaire pharma-pricing activist, an early ICER backer, funds new patient group's campaign

Big Pharma might not like billionaire hedge funder John Arnold’s next drug pricing move, a $500,000 contribution to the newfound Patients for …

Health Care

Stada's first real bidder has put up a $3.7B offer. Will a bidding war follow?

Stada's first real bidder has put up a $3.7B offer. Will a bidding war follow? chelfand Thu, 02/23/2017 - 09:28

Markets

China updates national drug list, adding some blockbuster Western meds

China has updated its list of medicines covered by national medical insurance, adding some new drugs with a focus on pediatrics and major illnesses …

Health Care

Priority review for Pfizer’s ALL drug

US regulators have agreed to undertake a speedy review of Pfizer's experimental drug inotuzumab ozogamicin as a treatment for adult patients with …

Medicine

New Group Takes on Drug Prices and Big Pharma

It's a good time to be an advocate for lower drug prices.<p>Congress is happily hauling drug company executives front and center to explain rising drug prices. The latest: Spencer Williamson, president and CEO of Kaleo Pharmaceuticals, which makes an injector device for the overdose drug …

Health Care

Perspectives: Drug Prices Are Meaningless — And That’s The Problem

Read recent commentaries about drug-cost issues.<p>Los Angeles Times: Big Pharma Really, Really Doesn't Want You To Know The True Value Of Its Drugs <br>The …

Health Care

MSD, Wayra unveil Velocity Health winners

Merck Sharp & Dohme (MSD) and Wayra UK have unveiled the 2017 winners of Velocity Health, a ground-breaking preventative digital healthcare …

Health Care

Annoying, Disgusting, Effective: Pharma TV Character Actors Embrace Quirkiness at Every Turn

Most Popular<p>Ilana Becker can barely go a day without someone asking her, "'You're the girl with the stomach, right?' "<p>Many actors are known for their …

Advertising Industry

Pharmacist fights for licence after fake drugs found at children's hospital

Thousands of counterfeit prescription pills made their way into Australia's official supply chain and ended up at a children's hospital in Sydney, an …

Australian News

Bayer's hefty 2016 pharma growth underlines danger of neglecting R&D for Monsanto buy

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. Prescription drug sales expanded by 8.7% …

Markets

Icahn has snapped up a Bristol-Myers stake. Could megamerger pressure be far behind?

What a difference one failed trial makes. After Bristol-Myers Squibb’s immunotherapy Opdivo fell short in a key lung cancer study last fall, the …

Wall Street

Amgen strikes Enbrel 'outcomes' contract with Harvard Pilgrim as biosimilar competition looms

Biosimilar competition for Amgen’s blockbuster rheumatoid arthritis drug Enbrel is lurking in the background but the biotech may have found a way to …

Investing

With new testosterone data, AbbVie's AndroGel faces more questions about heart risks

AbbVie’s former blockbuster testosterone-replacement treatment AndroGel will be at the center of a class action lawsuit set to go to trial this year, …

Medicine